Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Secondary Oral Vancomycin Prophylaxis for Recurrent Clostridioides difficile Infection

FY 2024-25

Summary
Clostridioides difficile (C. difficile) is a bacterial infection of the colon that can cause life-threatening diarrhea. It is the most common hospital-acquired infection, with over 16,000 cases reported yearly in Canada. The attributable cost of C. difficile in Canada is over 100 million dollars annually. Antibiotic use, which depletes the healthy gut flora, is the strongest risk factor for C. difficile infection. While C. difficile is treatable with oral C. difficile-active antibiotics, 20-30% of patients will have a recurrence of the infection within 90 days of treatment. The most common cause of recurrence is antibiotic use for another infection (referred to as systemic antibiotics), which occurs in 30-40% of patients recovering from C. difficile. Oral vancomycin is the first-line treatment for C. difficile in Quebec and is very safe, inexpensive, and accessible. Some studies have suggested that giving low-dose oral vancomycin during systemic antibiotics in patients with recent C. difficile infection may reduce the risk of recurrent C. difficile. However, the data isconflicting and of poor quality. Therefore, we aim to conduct a review of the current evidence on vancomycin prophylaxis, an international survey of clinicians on their use of C. difficile prophylaxis, and, ultimately, to conduct a randomized controlled trial comparing vancomycin to placebo for the prevention of recurrent C. difficile in patients re-exposed to systemic antibiotics. These studies will inform the use of vancomycin for the prevention of recurrent C. difficile and may reduce the recurrence rate of C. difficile.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530252
Name
Prosty Connor
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Secondary Oral Vancomycin Prophylaxis for Recurrent Clostridioides difficile Infection
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clostridioides Difficile; Colitis; Diarrhea; Prophylaxis; Vancomycin
Abstract
Clostridioides difficile (C. difficile) is a bacterial infection of the colon that can cause life-threatening diarrhea. It is the most common hospital-acquired infection, with over 16,000 cases reported yearly in Canada. The attributable cost of C. difficile in Canada is over 100 million dollars annually. Antibiotic use, which depletes the healthy gut flora, is the strongest risk factor for C. difficile infection. While C. difficile is treatable with oral C. difficile-active antibiotics, 20-30% of patients will have a recurrence of the infection within 90 days of treatment. The most common cause of recurrence is antibiotic use for another infection (referred to as systemic antibiotics), which occurs in 30-40% of patients recovering from C. difficile. Oral vancomycin is the first-line treatment for C. difficile in Quebec and is very safe, inexpensive, and accessible. Some studies have suggested that giving low-dose oral vancomycin during systemic antibiotics in patients with recent C. difficile infection may reduce the risk of recurrent C. difficile. However, the data isconflicting and of poor quality. Therefore, we aim to conduct a review of the current evidence on vancomycin prophylaxis, an international survey of clinicians on their use of C. difficile prophylaxis, and, ultimately, to conduct a randomized controlled trial comparing vancomycin to placebo for the prevention of recurrent C. difficile in patients re-exposed to systemic antibiotics. These studies will inform the use of vancomycin for the prevention of recurrent C. difficile and may reduce the recurrence rate of C. difficile.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Prosty, Connor
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~